scholarly journals Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura

2015 ◽  
Vol 8 (7) ◽  
pp. 35 ◽  
Author(s):  
Mohamadreza Amiri
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Eradication Therapy ◽  
Current Treatment ◽  
Thrombocytopenic Purpura ◽  
Stool Antigen Test ◽  
Platelet Counts ◽  
Before And After ◽  
History Of ◽  
H Pylori

<p>This study was a before and after clinical evaluation of <em>Helicobacter pylori</em> eradication on platelet counts in a group of 23 patients with chronic Idiopathic (Autoimmune) thrombocytopenic purpura (CITP). <em>H. pylori </em>infection was identified in patients by a <sup>13</sup>C-urea breath test and confirmed by an <em>H. pylori</em> stool antigen test. Eradication was conducted in patients testing positive. Infected (<em>n</em> = 10) and uninfected (<em>n</em> = 13) patient groups did not differ with respect to age, gender, history of previous splenectomy, treatment with anti-D, current treatment with corticosteroids, or initial platelet count<strong>s</strong>. <em>H pylori</em> eradication was successful in eight infected CITP patients, with two patients not responsive to treatment. Compared to the uninfected group, patients in the infected group who responded to eradication therapy had significantly increased platelet counts after six months (56.2 ± 22.2 <em>vs.</em> 233 ± 85.6 ×10<sup>3</sup> million cells/L; <em>P </em>&lt; 0.01), whereas platelet counts in the non-responding patients and uninfected group did not differ after this period of time. <em>H. pylori</em> eradication promotes significant platelet count improvement in patients with CITP. Thus, all patients with CITP should be tested and treated for<em> H. pylori </em>infections.</p>

scholarly journals PLATELET COUNT RESPONSE TO HELICOBACTER PYLORI ERADICATION IN IRANIAN ‎PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC ‎PURPURA

2012 ◽  
Vol 4 (1) ◽  
pp. e2012056 ◽  
Author(s):  
Mohammad Erfan Zare
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Eradication Therapy ◽  
Complete Response ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
Count Response ◽  
Significant Difference ◽  
H Pylori

Idiopathic thrombocytopenic purpura (ITP) is an autoimmune hematological disordercharacterized by auto antibody-mediated platelet destruction. Although the main cause of ITPremains unclear, but its relationship with some infection was demonstrated. In recent years, many studies have demonstrated improvement of platelet counts in ITP patients after treating Helicobacter pylori infection. The aim of this study was to investigate the effects of H. pylori eradication on platelet count response in Iranian ITP patients.A total of 26 patients diagnosed with both ITP and H. pylori infection. ITP were diagnosed whose platelet counts were less than 100×103/μL. These patients were tested for H. pylori infection by Urea Breath Test and serum H. pylori antibody. All patients received triple therapy for 7 or 14 days to eradicate H. pylori infection. These patients followed for six months.Prevalence of H. pylori was 67.3%. H. pylori eradication achieved in 89.5% (26/29). Of the 26 patients, 15 (57.7%) exhibited a complete response (CR) and 11 (42.3%) were unresponsive. We did not find partial responders. There was a significant difference in the baseline platelet count of responders and non-responders patients (p<0.001). All responders had platelet count ≥50×103/μLand all non-responders had platelet count <50×103/μL.Results of this study revealed that eradication therapy of H. pylori infection can improve platelet counts in ITP patients especially with mild thrombocytopenia and support routine detection andtreatment of H. pylori infection in ITP patients in populations with a high prevalence of this infection.

Correlation between Helicobacter Pylori Eradication and Platelet Count in Immune Thrombocytopenic Purpura (ITP).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4003-4003 ◽  
Author(s):  
Jun Ho Jang ◽  
Hyeoung Il Kim ◽  
Hyun Woo Lee ◽  
Seok Yun Kang ◽  
Joon Seong Park ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Immune Thrombocytopenic Purpura ◽  
Systemic Disease ◽  
Eradication Therapy ◽  
Thrombocytopenic Purpura ◽  
Duodenal Ulcers ◽  
Autoimmune Thyroid ◽  
Platelet Counts ◽  
H Pylori

Abstract BACKGROUND: Helicobacter pylori has clearly been implicated in the pathogenesis of gastric and duodenal ulcers, gastritis, and gastric malignancy. Remarkably, eradication of H. pylori from the gastric mucosa has been associated with improvement of systemic disease, including Sjögren’s syndrome, rheumatoid arthritis, autoimmune thyroid disease, and immune thrombocytopenic purpura (ITP). PURPOSE: To investigate the relationship between Helicobacter pylori infection and the clinical features of idiopathic thrombocytopenic purpura (ITP), and to examine the effects of H. pylori eradication on platelet counts. METHOD: A 13C urea breath test (UBT) for H. pylori infection was performed in a 25 consecutive patients with ITP at Ajou University School of Medicine, Suwon, Korea. Patients who tested positive for H. pylori received standard eradication therapy if their platelet count was &lt; 50 x 109/L. RESULTS: H. pylori infection was detected in 18 patients (72%) and eradication therapy was successfully administered to all infected patients. H. pylori infection was not associated with dyspepsia or other clinical or laboratory features. Platelet responses were observed in 6 (33%) of these patients, which lasted for more than 4 months in 4 patients. Platelet associated antibody and anti platelet antibody were negative to all patients. CONCLUSION: H. pylori eradication may improve the platelet counts in some of adults (33%) in whom the ITP is of recent onset.

Does Helicobacter pylori Eradication Therapy Result in a Platelet Count Improvement in Adults with Immune Thrombocytopenic Purpura Regardless of H pylori Infection?

Hematology ◽  
2008 ◽  
Vol 2008 (1) ◽  
pp. 31-32 ◽  
Author(s):  
Donald M. Arnold ◽  
Roberto Stasi
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Immune Thrombocytopenic Purpura ◽  
Eradication Therapy ◽  
Thrombocytopenic Purpura ◽  
Helicobacter Pylori Eradication ◽  
History Of ◽  
H Pylori ◽  
Helicobacter Pylori Eradication Therapy ◽  
Therapy Result

AbstractA 34-year-old male with a long history of immune thrombocytopenic purpura (ITP) presents to your office. His platelet count is 30 × 109/L and he is clinically stable with no bleeding symptoms. He has read that Helicobacter pylori eradication therapy may be effective for ITP and he asks you about this. You do not have access to reliable tests for H pylori infection (e.g., urea breath test), yet you wonder about the benefit of empiric eradication therapy for your patient.

Clinical Features and Effects of Eradication on Helicobacter Pylori Positive 207 ITP Cases in Japan.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2071-2071
Author(s):  
Kingo Fujimura ◽  
Masataka Kuwana ◽  
Yoshiyuki Kurata ◽  
Masahiro Imamura ◽  
Hiroshi Harada ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Eradication Therapy ◽  
The Other ◽  
First Line ◽  
Platelet Counts ◽  
Count Response ◽  
Successful Group ◽  
H Pylori ◽  
Over 40 Years

Abstract In 1998, Gasbarrini et al reported that in ITP cases with Helicobacter pylori (H.pylori) infection, elevation of platelet counts was observed by eradication of this bacterium. Since then, several reports from Italy and Japan confirmed the elevation of platelet counts after eradication. However, the characteristic background in the H.pylori positive ITP and eradication effects on platelet counts is unclear. On the other hand, reports from Spain, North Europe and USA could not show the evidence that eradication is effective on elevating platelet counts in H.pylori positive ITP. Therefore, we designed a nationwide retrospective study in Japan to evaluate the incidence of H.pylori positive ITP cases and the effects of eradication on platelet counts and to clear above problems. Four hundred and thirty-five ITP cases were enrolled over a period of one and half years (2002. 7~2003.12) from 12 hospitals. H. pylori infection was found in 300 cases(65%), who were significantly (P<0.005) older and showed hyperplastic megakaryocyte in bone marrow (P=0.011) comparison with negative cases. Eradication to H. pylori was performed in 207 H. pylori positive ITP cases and as a whole, the platelet count response was observed in 63% of eradication succeeded group. In the successful group, CR and PR rate were 23% and 42% respectively at 12 months after eradication. The platelet count response was significant in the successfully eradicated group (P<0.005) and the increased platelet count was maintained without ITP treatment for over 12 months. In conclusion, H. pylori infection was involved in most ITP patients over 40 years old in Japan and eradication therapy proved effective for increasing platelet counts even in splenectomy non-responsive cases and the platelet count response appeared one month after eradication. This evidence suggests that eradication therapy is the first line of treatment in H. pylori positive ITP patients.

scholarly journals Role of Helicobacter pylori Eradication Therapy on Platelet Recovery in Chronic Immune Thrombocytopenic Purpura

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Khan Sheema ◽  
Ujjan Ikramdin ◽  
Naz Arshi ◽  
Naz Farah ◽  
Sheikh Imran
Keyword(s):  
Bone Marrow ◽  
Helicobacter Pylori ◽  
Immune Thrombocytopenic Purpura ◽  
Eradication Therapy ◽  
Bone Marrow Examination ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
Chronic Immune Thrombocytopenic Purpura ◽  
Chronic Itp ◽  
H Pylori

Background. Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder in which the immune system destroys native platelets. In this condition an autoantibody is generated against a platelet antigen. ITP affects women more often than men and is more common in children than adults. Objective. To assess the effect of Helicobacter pylori eradication therapy (HPET) on platelet count in Helicobacter pylori associated chronic immune thrombocytopenic purpura (chronic ITP) in adult. Materials and Methods. It is an interventional prospective study conducted at Liaquat University of Medical and Health Sciences, Jamshoro, from 2014 to 2015. A set of 85 patients diagnosed with chronic ITP were included in the study via convenient sampling. Patients with platelets count < 100 × 109/L for >3 months were selected. They were posed to first-line investigations which comprised complete blood count (CBC) and peripheral blood smear examination followed by second-line tests including bone marrow examination and Helicobacter pylori stool specific antigen (HpSA-EIA). Standard H. pylori eradication therapy was offered and the patients were assessed at regular intervals for 6 months. Results. Of the 85 study patients, 32 (37.6%) were male and 53 (62.3%) were female. Mean ages of H. pylori positive and negative subjects were 43.89 ± 7.06 and 44.75 ± 7.91 years, respectively. Bone marrow examination confirmed the diagnosis and excluded other related BM disorders. H. pylori stool antigen (HpSA) was detected in 34 (40%) patients and hence regarded as H. pylori positive; the rest were negative. Treatment with eradication therapy significantly improved the mean platelet counts from 48.56±21.7 × 109/l to 94.2±26.8 × 109/l. Conclusion. We concluded that the anti-H. pylori eradication therapy improves blood platelet counts in chronic immune thrombocytopenia.

scholarly journals Variations in Mean Platelet Volume in Patients with Helicobacter pylori Infection before and after Eradication, Way before Immune Thrombocytopenia?

Proceedings ◽  
2018 ◽  
Vol 2 (9) ◽  
pp. 529
Author(s):  
Burcu Dag ◽  
Elif G. Umit ◽  
Hasan Umit
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Mean Platelet Volume ◽  
Immune Thrombocytopenia ◽  
Platelet Volume ◽  
Platelet Counts ◽  
Normal Platelet ◽  
Urease Test ◽  
Before And After ◽  
H Pylori

Helicobacter pylori (H. pylori) and immune thrombocytopenia (ITP) association is well known and eradication treatment has its place in both treatment guidelines. Since H. pylori eradication is followed by an increase in platelet counts in patients with immune thrombocytopenia, it is suggested that H. pylori be examined and treated if infection is present. There is only one study that demonstrated a relation between H. pylori and platelet indices in individuals with normal platelet counts. In this study, we aimed to investigate the effects of H. pylori infection on platelet count and mean platelet volume, which is a sign of increased platelet destruction in patients with normal platelet counts. We evaluated the data of 106 patients with urease test positivity before the eradication of bacteria and urea breath test negative after the eradication, in a retrospective manner. Mean platelet count in patients before the eradication treatment was 256.730 ± 66.380/mm3. After H. pylori was eradicated, it has been observed that the mean platelet count increased to 287.080 ± 59.240/mm3. Mean MPV of patients before and after eradication treatment were 9.35 ± 1.63 fL and 8.61 ± 1.48 fL. Mean MPV was higher when patients were infected with H. pylori. This study showed that there is an increase in platelet counts and a decrease in MPV levels with the eradication of the H. pylori. Our study is the first to investigate changes of mean platelet volume and platelet count before and after eradication of H. pylori infection in individuals with normal platelet counts.

scholarly journals An Unusual Cause of Secondary ITP in a 34-Year-Old Hispanic Male

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Ayrton Bangolo ◽  
Mohamed Ahmed ◽  
Ali Atoot ◽  
Ashraf Mahmoud ◽  
Chibuzo Agbakwuru-Onyike ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Case Report ◽  
Geographic Distribution ◽  
Immune Thrombocytopenic Purpura ◽  
Severe Thrombocytopenia ◽  
Thrombocytopenic Purpura ◽  
Platelet Counts ◽  
H Pylori ◽  
Hispanic Male

Secondary immune thrombocytopenic purpura (ITP) associated with Helicobacter pylori (H. pylori) infection has been described in the literature. It appears to have a geographic distribution; mostly encountered in countries with a higher prevalence for H. pylori such as Italy or Japan. H. pylori eradication has been recommended in the management of ITP with studies showing improvement in the platelet count in some patients. Substantial platelet count increases in patients with severe thrombocytopenia (platelet counts <30 × 103 microliter), however, are uncommon with H. pylori treatment alone. Here, we present a 34-year-old Hispanic male with worsening chronic thrombocytopenia that resolved following eradication of his H. pylori infection. Herein, we highlight a rare and reversible cause of secondary ITP. With this case report, we hope to encourage physicians to include H. pylori testing in the evaluation of thrombocytopenia.

scholarly journals Effect of Helicobacter pylori infection on the first-line treatment outcomes in patients with immune thrombocytopenic purpura

2021 ◽  
Author(s):  
Ali Dogan ◽  
Omer Ekinci ◽  
Senar Ebinc
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Immune Thrombocytopenic Purpura ◽  
Eradication Therapy ◽  
Line Treatment ◽  
First Line ◽  
Thrombocytopenic Purpura ◽  
Significant Difference ◽  
H Pylori ◽  
First Line Treatment

Background: Helicobacter pylori (H. pylori) eradication therapy is known to increase the platelet count, but in immune thrombocytopenic purpura (ITP), the effect of H. pylori infection on the response to treatment is not clear. This study aims to determine whether the response to the first–line treatment is affected by the states of H. pylori–positivity and –negativity in ITP patients. Methods: Adult newly diagnosed or chronic ITP patients who had not received eradication therapy for H. pylori infection were included. Characteristics of the patients, presence and severity of bleeding, initial platelet count, administered treatments, and treatment response rates were inspected. Results: Of 119 total patients, 32 (26.9%) were H. pylori–positive, 87 (73.1%) were H. pylori–negative. The most common treatment was standard–dose steroid in both groups (62.5% vs 68.9%, p=0.524). Rates of complete response, partial response, no response were comparable for the two groups (respectively, 75% vs 73.6%, and 18.8% vs 19.5%, and 6.2% vs 6.9%), and there was no significant difference between the groups (p=0.283). Conclusion: It can be stated according to the present study that; in ITP patients in whom treatment is indicated, the response to the first–line treatment without the administration of H. pylori eradication therapy is comparable between H. pylori–positive and H. pylori–negative patients. Keywords: Helicobacter pylori, immune thrombocytopenic purpura, first-line treatment

scholarly journals Helicobacter pylori induced Immune Thrombocytopenic Purpura and perspective role of Helicobacter pylori eradication therapy for treating Immune Thrombocytopenic Purpura

2021 ◽  
Vol 7 (3) ◽  
pp. 284-303
Author(s):  
Arham Ihtesham ◽  
◽  
Shahzaib Maqbool ◽  
Muhammad Nadeem ◽  
Muhammad Bilawal Abbas Janjua ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Immune Thrombocytopenic Purpura ◽  
Treatment Efficacy ◽  
Molecular Mimicry ◽  
Eradication Therapy ◽  
Surface Antigens ◽  
Thrombocytopenic Purpura ◽  
Platelet Surface ◽  
H Pylori

<abstract> <p>Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterised by production of autoantibodies against platelet surface antigens. Recent studies have demonstrated a paramount association of ITP and <italic>Helicobacter pylori (H-pylori)</italic> infection with significant rise in platelet count following <italic>H-pylori</italic> eradication therapy. The <italic>H-pylori</italic> infection induced ITP is validated by many proposed mechanisms such as molecular mimicry due to production of autoantibodies against <italic>H-pylori</italic> surface virulent factors (CagA) and cross reactivity of these antibodies with platelet surface antigens (GP IIb/IIIa, GP Ib/IX, and GP Ia/IIa), phagocytic perturbation due to enhanced phagocytic activity of monocytes, enhanced dendritic cell numbers and response, platelets aggregation due to presence of anti- <italic>H-pylori</italic> IgG and von Willebrand factor (vWf) and finally host immune response against <italic>H-pylori</italic> virulent factors CagA and VacA leading to ITP. The effectiveness of <italic>H-pylori</italic> eradication therapy has also been demonstrated with platelet count being used as a predictive factor for assessment of treatment efficacy. Out of 201 patients 118 were responding to the triple therapy and remaining 83 patients were non-responders, showing the response rate of 58.7%. Out of 118 responders 69 patients were showing complete response (CR) and 49 were showing partial response (PR) to the <italic>H-pylori</italic> eradication therapy. However, more studies are required to elucidate this association and treatment efficacy.</p> </abstract>

scholarly journals Efficacy of Helicobacter pylori Eradication Therapy on Platelet Recovery in Pediatric Immune Thrombocytopenic Purpura-Case Series and a Systematic Review

2020 ◽  
Vol 8 (10) ◽  
pp. 1457
Author(s):  
Tamaki Ikuse ◽  
Masanori Toda ◽  
Kosuke Kashiwagi ◽  
Kimiko Maruyama ◽  
Masumi Nagata ◽  
...  
Keyword(s):  
Systematic Review ◽  
Helicobacter Pylori ◽  
Immune Thrombocytopenic Purpura ◽  
Pediatric Patients ◽  
Eradication Therapy ◽  
Platelet Response ◽  
Thrombocytopenic Purpura ◽  
Helicobacter Pylori Eradication ◽  
H Pylori ◽  
Helicobacter Pylori Eradication Therapy

Evidence relating to the efficacy of Helicobacter pylori eradication therapy for chronic immune thrombocytopenic purpura (cITP) in childhood is inadequate. The aim of this retrospective study was to determine the efficacy of H. pylori eradication therapy for platelet response in pediatric patients with cITP in our hospital, and to perform a systematic review of previous reports about pediatric patients with cITP who were positive for H. pylori infection and were treated with H. pylori eradication therapy. Analysis of the data of pediatric patients with cITP in our hospital and a systematic review of digital literature databases of studies in pediatric patients with cITP were performed. Data of 33 pediatric patients with cITP from our hospital records showed that the prevalence of H. pylori infection and the rate of response to platelet therapy were 15% and 33.3%, respectively. Data of 706 pediatric patients from 18 previous reports showed that the prevalence of H. pylori infection and rate of platelet response were 23% and 43.8%, respectively. Eradication therapy for H. pylori infection in pediatric cITP patients can be expected to result in a response equivalent to that in the adult population, with fewer adverse effects than other treatments for cITP.

Sign in / Sign up

Export Citation Format

Share Document